NCT00840333View on ClinicalTrials.gov

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Cystic Fibrosis

Interventions

DRUG

MP-376 (Levofloxacin solution for Inhalation)

DOSE BASED ON PATIENTS WEIGHT

Trial Locations (6)

Unknown

Mobile

San Diego

Orlando

Louisville

Kansas City

Akron

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY